Edgewise is exploring therapies for the treatment of cardiac muscle disorders using a novel mechanism of action, currently being researched.
In particular, we are working to alleviate the potentially harmful effects resulting from hypertrophic cardiomyopathy (HCM). HCM is the most common inherited cardiac disorder, resulting in atypical thickening of heart muscle, as well as irregular arrangement of heart muscle cells, known as myofiber disarray. HCM is estimated to occur in one in 500 people worldwide, and there is currently no known prevention for HCM. Thickened heart muscle resulting from HCM can contribute to significant health problems, including shortness of breath, chest pains, arrhythmias, atrial fibrillation, decreased blood flow, mitral valve issues, heart failure, or sudden cardiac death.